#United States #Philadelphia #OSR Holdings #Darnatein #BMP Conference

Darnatein to Present at the 14th International BMP Conference

Darnatein, a significant player in the biotechnology sector and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), has recently announced its participation in the 14th International Bone Morphogenetic Protein (BMP) Conference, scheduled for May 2 to 6, 2025, at the University of Pennsylvania, Philadelphia. This renowned conference gathers some of the brightest minds in the field of regenerative medicine, focusing on the latest developments surrounding BMP-related biology.

What to Expect at the BMP Conference

The BMP Conference serves as a platform for leading global researchers to share their findings and insights on biological processes related to bone morphogenetic proteins. This year, the conference underscores advancements in tissue and organ regeneration technologies, highlighting the integration of fundamental research with practical applications. For more detailed information, interested parties can visit the event's official website at 14th BMP Conference.

Darnatein's CEO, Dr. Senyon "Teddy" Choe, is set to present intriguing scientific data on May 3. His presentation, entitled "Design-Augmented Synthetic BMP Chimeras as Super-Agonists for Bone and Cartilage Regeneration," will introduce Darnatein's proprietary technology and show how it has led to the creation of two promising biologic candidates: DRT-101 and DRT-102.

Innovations in Biologics: DRT-101 and DRT-102

DRT-101 is focused on joint cartilage regeneration, displaying a strong preclinical safety profile, while DRT-102 is dedicated to spinal bone repair. Dr. Choe's presentation will highlight these products' efficacy as BMP super-agonists, emphasizing their potential to significantly advance therapeutic outcomes for those suffering from musculoskeletal disorders.

Dr. Choe stated, "This presentation reflects Darnatein's growing leadership in synthetic regenerative biologics. Our DA Biologics platform is enabling the creation of highly potent, next-generation growth factors with the potential to transform musculoskeletal repair."

Furthermore, Darnatein’s presence at the BMP Conference highlights a year of remarkable progress, including:

• - Preclinical Validation: Successful results for DRT-101 and DRT-102, showcasing enhanced safety and regeneration of cartilage and bone.
• - Collaborative Research: Ongoing IND-enabling studies in partnership with BioToxTech, a publicly-listed Contract Research Organization in South Korea, and the University of California, San Diego. This collaboration aims to advance DRT-101 toward IND submissions with both the Korean MFDS and the U.S. FDA.

Commitment to Regenerative Medicine

The commitment of Darnatein to expand its Design-Augmented Biologics platform illustrates its ambition to address unmet needs globally in the field of regenerative medicine. By leveraging cutting-edge synthetic biology and protein engineering, Darnatein is well-positioned to contribute valuable innovations to the healthcare landscape.

About Darnatein

Darnatein specializes in the development of design-augmented biologics tailored for regenerative medicine. With a keen focus on utilizing synthetic biology and protein engineering, they are developing next-generation growth factors aimed at musculoskeletal and tissue repair. The lead candidates, DRT-101 and DRT-102, are pivotal innovations targeting joint cartilage and spinal bone regeneration, respectively.

About OSR Holdings

A global healthcare company, OSR Holdings, Inc. (NASDAQ: OSRH), is dedicated to improving health outcomes and quality of life. OSR aims to build a robust portfolio of innovative therapies that can potentially transform patient care. Current operations include oral immunotherapies for cancer treatment and the development of cutting-edge biologics for degenerative diseases.

In anticipation of sharing their advancements, Darnatein is excited to engage with fellow researchers and clinicians at the BMP Conference, paving the way for future breakthroughs in regenerative medicine.